Thyroid and Breast Department, Extra-Thyroid and Breast Neoplasms, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Department of Thyroid and Breast III, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Aging (Albany NY). 2021 Jul 22;13(14):18498-18514. doi: 10.18632/aging.203298.
Breast cancer (BC) is a common malignant tumor in females. The challenge in treating BC is overcoming chemoresistance. Exosome-mediated transfer of miRNAs is a molecule-shuttle in intercellular communication. Thus, we aimed to investigate whether exosomal miRNA-205 could affect chemoresistance and tumorigenesis in recipient tumor cells and to elucidate the underlying mechanism and . Microarray and qRT-PCR assays demonstrated that miRNA-205 was upregulated in tamoxifen resistance MCF-7/TAMR-1 (M/T) cells and M/T cell-derived exosomes (M/T-Exo). The M/T-Exo was internalized by human BC cells (BCCs), causing increased expression of miRNA-205 in BCCs. Coculturing with M/T-Exo promoted tamoxifen resistance, proliferation, migration, and invasion while suppressed apoptosis in recipient BCCs, which were associated with activating the caspase pathway and phosphorylating Akt. Luciferase reporter assays showed that miRNA-205 directly targeted E2F Transcription Factor 1 (E2F1) in BCCs. Furthermore, knockdown of miRNA-205 or overexpression of E2F1 reversed the roles of M/T-Exo in BCCs. experiments showed that the intratumoral injection of M/T-Exo caused greater tamoxifen resistance and larger tumor size relative to mice treated with miRNA-205-knockdown or E2F1-overexpressing BCCs. Together, the results suggest that exosomal miRNA-205 may promote tamoxifen resistance and tumorigenesis in BC through targeting E2F1 and .
乳腺癌(BC)是女性常见的恶性肿瘤。治疗 BC 的挑战在于克服化疗耐药性。外泌体介导的 miRNA 转移是细胞间通讯的分子穿梭。因此,我们旨在研究外泌体 miRNA-205 是否可以影响受体肿瘤细胞的化疗耐药性和肿瘤发生,并阐明其潜在机制。微阵列和 qRT-PCR 分析表明,miRNA-205 在他莫昔芬耐药 MCF-7/TAMR-1(M/T)细胞和 M/T 细胞衍生的外泌体(M/T-Exo)中上调。M/T-Exo 被人乳腺癌细胞(BCCs)内化,导致 BCCs 中 miRNA-205 的表达增加。与 M/T-Exo 共培养促进了他莫昔芬耐药、增殖、迁移和侵袭,同时抑制了受体 BCCs 的凋亡,这与激活半胱氨酸天冬氨酸蛋白酶途径和磷酸化 Akt 有关。荧光素酶报告基因实验表明,miRNA-205 可直接靶向 BCCs 中的 E2F 转录因子 1(E2F1)。此外,miRNA-205 的敲低或 E2F1 的过表达逆转了 M/T-Exo 在 BCCs 中的作用。体内实验表明,与 miRNA-205 敲低或 E2F1 过表达的 BCC 治疗的小鼠相比,M/T-Exo 的肿瘤内注射导致更大的他莫昔芬耐药性和更大的肿瘤体积。总之,这些结果表明,外泌体 miRNA-205 可能通过靶向 E2F1 促进 BC 中的他莫昔芬耐药性和肿瘤发生。